Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Activated factor X(FXa) stimulants as new antihemorrhagic agents for topical use

A blood coagulation factor, local treatment technology, applied in the direction of anti-inflammatory agents, medical preparations containing active ingredients, blood diseases, etc., can solve the problems of unstable fibrin clots, dangerous side effects, lack of acute effects, etc., to improve protein The effect of hydrolytic activity

Inactive Publication Date: 2008-10-22
THROMBOTARGETS EURO SL
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

(2) Administration requires special equipment
(4) Unable to provide appropriate or convenient treatment for specific bleeding events
(5) Lack of acute effect
(7) The side effects are very dangerous
In this patent application, the inventors demonstrated that phospholipids (phosphatidylserine and phosphatidylcholine in different percentages and molar concentrations) do not enhance the procoagulant effect mediated by lipidated TF (Table 21), which indicates that U.S. Patent No. 4,721,618 No. and WO02 / 086118 the claimed synergy is limited to serine protease-activated coagulation factors and does not apply to membrane receptors such as TF

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Activated factor X(FXa) stimulants as new antihemorrhagic agents for topical use
  • Activated factor X(FXa) stimulants as new antihemorrhagic agents for topical use
  • Activated factor X(FXa) stimulants as new antihemorrhagic agents for topical use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

Embodiment 2

Embodiment 3

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The activated coagulation Factor X (FXa) stimulating agents may be used in the treatment of hemorrhages in a subject. Compounds and combinations are described which are particularly useful for the topical treatment of hemorrhaging in healthy subjects or in patients with hemorrhagic diathesis.

Description

Stimulators of activated factor X (FXa) as new topical antihemorrhagic agents field of invention The present invention relates to the topical treatment of bleeding in an individual through the use of FXa stimulators. The present invention is based on the discovery that lipidated tissue factor (TF) exhibits a novel regulatory action that stimulates all proteolytic activity of both forms of FXa, soluble FXa and FXa bound to the prothrombinase complex (amidolytic activity and prothrombin hydrolytic activity). Background of the invention 1. Physiology of coagulation Hemostasis is the mechanism by which an organism responds to bleeding that involves the participation of two processes that act immediately after injury and remain active for long periods of time. The first process, known as primary hemostasis, is characterized by vasoconstriction and formation of platelet aggregates at the site of vascular injury. The second process is called secondary hemostasis, during which...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/36A61P7/04
CPCA61K38/36A61P1/00A61P7/02A61P7/04A61P9/10A61P25/28A61P29/00A61P35/00
Inventor 哈维尔·佩德雷尼奥埃赫亚路易斯·卡韦达卡塔苏斯
Owner THROMBOTARGETS EURO SL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products